Hair Loss Meds Give Back Mane, Take Sexual Function

Article

5a-reductase inhibitors in popular hair loss medications can produce persistent erectile dysfunction and depression, even after their use has been discontinued.

A new study published in The Journal of Sexual Medicine reveals that, for the first time, 5a-reductase inhibitors commonly used to treat urinary problems in patients with benign prostatic hyperplasia (BPH) and found in popular medications to treat hair loss, can produce, persistent erectile dysfunction (ED), depression and loss of libido, even after the medication has been discontinued.

Researchers led by Abdulmaged M. Traish, MBA, PhD, of Boston University School of Medicine, examined data reported in various clinical studies from the available literature concerning the side effects of the 5 alpha reductase inhibitors, finasteride and dutasteride.

Prolonged adverse side effects on sexual function, such as ED, depression and diminished libido, were reported by a subset of men. Drug-related reduction in libido occurred in 4.2% and 1.8% of patients in the dutasteride and placebo groups, respectively. Reduced ejaculation and semen volume were also reported and in some patients, these drugs were associated with depression.

"For these reasons, patients and doctors are urged to discuss these issues openly and candidly and assess the risk benefit ratio prior to commencing therapy with 5a-reductase inhibitors" Dr. Traish notes.

The Journal of Sexual Medicine,

Dr. Irwin Goldstein, editor-in-chief of has seen and evaluated numerous such patients. He further explained the importance of this study:

"Young men are being prescribed 5 alpha reductase inhibitors as hair loss treatments that may negatively impact their sexual life, possibly for a prolonged time after stopping the medication. Older men with symptoms of lower urinary tract symptoms or fearful of prostate cancer, now have to deal with new onset sexual and mental health problems. The growing use of 5 alpha reductase inhibitors is causing concerns."

Clearly more research is needed to better understand the basis for these drug-associated side effects but it is evident that 5 alpha reductase inhibitors prevent the synthesis of very critical central nervous system neurosteroids and lower a very important sex steroid hormone, dihydrotestosterone.

Source: Wiley-Blackwell

Recent Videos
Brendon Neuen, MBBS, PhD | Credit: X.com
Boadie Dunlop, MD, Weighs in on FDA Advisory Vote on Lykos’ MDMA
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Ralph DeFronzo, MD | Credit: UT San Antonio
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
Atul Malhotra, MD | Credit: Kyle Dykes; UC San Diego Health
Bhanu Prakash Kolla, MBBS, MD: Treating Sleep with Psychiatric Illness
Awaiting FDA Decision on MDMA Assisted Therapy, with Bessel van der Kolk, MD
Bessel van der Kolk, MD: The Future of MDMA Assisted Therapy in PTSD
Bessel van der Kolk, MD: What MDMA-Assisted Therapy Taught us About PTSD
© 2024 MJH Life Sciences

All rights reserved.